# Instituto Grifols, S.A. clinical trials: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Instituto Grifols, S.A. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Instituto Grifols, S.A.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/instituto-grifols-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 4, 2025 | NCT07264517 | Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). | Instituto Grifols, S.A. | Phase 2 | Completed | Dry Eye Disease | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264517) |
| November 19, 2020 | NCT04636268 | FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis | Instituto Grifols, S.A. | Phase 3 | Withdrawn | Congenital Afibrinogenemia, Hypofibrinogenemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04636268) |
| September 14, 2020 | NCT04547127 | A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease... | Instituto Grifols, S.A. | Phase 2 | Completed | COVID-19 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04547127) |
| July 31, 2020 | NCT04495101 | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | Instituto Grifols, S.A. | Phase 2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04495101) |
| June 16, 2020 | NCT04432324 | Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19) | Instituto Grifols, S.A. | Phase 2 | Completed | COVID-19 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04432324) |
| October 11, 2018 | NCT03702920 | Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5% | Instituto Grifols, S.A. | Phase 3 | Terminated | Acute-On-Chronic Liver Failure | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03702920) |
| March 12, 2018 | NCT03461406 | A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants | Instituto Grifols, S.A. | Phase 3 | Completed | Excessive Bleeding During Surgery | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03461406) |
| June 24, 2015 | NCT02479802 | Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis | Instituto Grifols, S.A. | Phase 2 | Completed | Amyotrophic Lateral Sclerosis | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02479802) |
| June 27, 2014 | NCT02176863 | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in... | Instituto Grifols, S.A. | Phase 2/3 | Terminated | Post-polio Syndrome | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02176863) |
| December 18, 2013 | NCT02014402 | Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery | Instituto Grifols, S.A. | Phase 2 | Completed | Hemostasis | 181 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02014402) |
| December 21, 2012 | NCT01754480 | Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries | Instituto Grifols, S.A. | Phase 3 | Completed | Parenchymous Tissue Surgical Bleeding | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01754480) |
| August 10, 2012 | NCT01662856 | Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery | Instituto Grifols, S.A. | Phase 3 | Completed | Vascular Surgical Bleeding | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01662856) |
| March 22, 2012 | NCT01561053 | A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease | Instituto Grifols, S.A. | Phase 2/3 | Completed | Alzheimer's Disease | 347 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01561053) |
| September 15, 2010 | NCT01201720 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic... | Instituto Grifols, S.A. | Not applicable | Completed | Liver Cirrhosis, Liver Failure | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01201720) |
| May 26, 2010 | NCT01131065 | Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients | Instituto Grifols, S.A. | Phase 3 | Completed | Hepatitis B, Liver Transplantation | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01131065) |
| August 31, 2009 | NCT00968695 | Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites. | Instituto Grifols, S.A. | Phase 4 | Completed | Cirrhosis, Ascites | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00968695) |
| May 8, 2009 | NCT00895713 | Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation | Instituto Grifols, S.A. | Phase 2 | Completed | Hepatitis B, Chronic | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00895713) |
| February 6, 2009 | NCT00838071 | Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation | Instituto Grifols, S.A. | Phase 3 | Completed | Hepatitis B, Chronic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00838071) |
| January 15, 2009 | NCT00823082 | Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass | Instituto Grifols, S.A. | Phase 2 | Completed | Acquired Antithrombin III Deficiency, Coronary Artery Bypass | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00823082) |
| August 27, 2008 | NCT00742417 | Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid | Instituto Grifols, S.A. | Phase 2 | Completed | Alzheimer's Disease | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00742417) |
| June 17, 2008 | NCT00699140 | Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura | Instituto Grifols, S.A. | Phase 3 | Completed | Immune (Idiopathic) Thrombocytopenic Purpura | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00699140) |
| May 26, 2008 | NCT00684047 | Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis | Instituto Grifols, S.A. | Phase 2/3 | Completed | Target Bleeding Site During Peripheral Vascular Surgery | 239 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00684047) |
| March 13, 2008 | NCT00634569 | Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects | Instituto Grifols, S.A. | Phase 4 | Completed | Primary Immune Deficiency Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00634569) |
| April 27, 2006 | NCT00319228 | Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate | Instituto Grifols, S.A. | Phase 2/3 | Terminated | Antithrombin III Deficiency | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00319228) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 9 |
| Phase 2/3 | 4 |
| Phase 3 | 8 |
| Phase 4 | 2 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 3 |
| Hepatitis B | 3 |
| Recurrence | 3 |
| Alzheimer Disease | 2 |
| Plaque, Amyloid | 2 |
| Hepatitis B, Chronic | 2 |
| Fibrosis | 2 |
| Afibrinogenemia | 1 |
| Dementia | 1 |
| Central Nervous System Diseases | 1 |
| Brain Diseases | 1 |
| Mental Disorders | 1 |
| Antithrombin III Deficiency | 1 |
| Hemostatic Disorders | 1 |
| Hematologic Diseases | 1 |
| Primary Immunodeficiency Diseases | 1 |
| Bruton type agammaglobulinemia | 1 |
| Hyper-IgM Immunodeficiency Syndrome | 1 |
| Wiskott-Aldrich Syndrome | 1 |
| Dry Eye Syndromes | 1 |
| Autoimmune Diseases | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Purpura, Thrombocytopenic | 1 |
| Liver Cirrhosis | 1 |
| Liver Failure | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lighting fixtures and equipment companies in the United States](https://specstream.ai/data/businesses/lighting-fixtures-and-equipment-companies/united-states)
- [Avionics shops in the United States](https://specstream.ai/data/businesses/avionics-shops/united-states)
- [Leather products manufacturers in the United States](https://specstream.ai/data/businesses/leather-products-manufacturers/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Asian fusion restaurants in the United States](https://specstream.ai/data/businesses/asian-fusion-restaurants/united-states)
